Summary
GBI Research, a leading
business intelligence provider, has released its latest research report,
"Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2020 -
Growth to Hinge on the Success of Personalized Vaccine Following Early Approval
in Germany".
Due to the poor
prognosis under currently available treatments, therapies with high potency are
in strong demand in the Glioblastoma Multiforme (GBM) market. In newly
diagnosed patients, the current standard of care, comprising resection surgery,
radiation therapy and chemotherapy with Merck's Temodar (temozolomide), has a
maximum Overall Survival (OS) of 15 months and almost inevitable tumor
recurrence. Current therapeutic options for recurrent GBM are Roche's Avastin
(bevacizumab), carmustine and other chemotherapy drugs used off-label. However,
they only offer limited OS benefit, leaving high unmet need in this patient
segment.
During the 2013-2020
forecast period, the GBM market is expected to grow rapidly from $301m to
$623m. The market entry of Northwest Biotherapeutics' DCVax-L, a dendritic
cell-based therapeutic vaccine that acts as an add-on to the standard treatment
in newly diagnosed patients, will account for much of this growth. Having
demonstrated superior OS improvement compared with the standard treatment alone
in clinical trials, it is expected to bear high market potential, given that
its efficacy is translated into larger Phase III trials. The cancer vaccine
Rindopepimut (CDX-110) and targeted therapy Cotara will also enter the GBM
market, but will drive growth to a lesser extent. However, unmet needs are
likely to remain in the relapsed setting over the forecast period due to the
lack of superior OS benefits in the late-stage pipeline.
About Radiant Insights
Radiant Insights is a platform for companies looking to meet
their market research and business intelligence requirements. We assist and
facilitate organizations and individuals procure market research reports,
helping them in the decision making process. We have a comprehensive collection
of reports, covering over 40 key industries and a host of micro markets. In
addition to over extensive database of reports, our experienced research
coordinators also offer a host of ancillary services such as, research
partnerships/ tie-ups and customized research solutions.
For More Information Visit – Radiant Insights
Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com
No comments:
Post a Comment